Admarib-100/150
Admarib-100/150 - Image 2

Admarib-100/150

Generic Name– Olaparib
Drug Class – Antineoplastic Agent / PARP (Poly ADP-Ribose Polymerase) Inhibitor
Olaparib is an oral chemotherapy drug used to treat certain types of cancers associated with BRCA1/2 mutations, including ovarian, breast, pancreatic, and prostate cancers.
It works by inhibiting the PARP enzyme, which is involved in DNA repair. By blocking this enzyme, Olaparib causes cancer cells with defective DNA repair mechanisms to accumulate damage and undergo cell death.
Olaparib is administered orally in tablet form, usually under the supervision of an oncologist, and may be used as monotherapy or in combination with other treatments.
Common side effects include nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, and respiratory infections. Blood counts should be monitored regularly during therapy.

Dosage: Available in 100 mg and 150 mg tablets

Category: Oral Tablet

Category:

Indications & Usage

Dydrogesterone is indicated for:

  • Prevention of natural abortion in adult patients who have a history of habitual abortions (Threatened or Recurrent Miscarriage)
  • Treatment option for patients with dysmenorrhea (severe and frequent menstrual cramps and pain during the period)
  • Treatment of endometriosis, a condition with abdominal pain and menstrual irregularities as common symptoms

Clinical Efficacy

  • First clinical treatment choice due to its the good oral bioavailability and lesser risk of developing breast or endometrial cancer compared to other progestagens
  • Shown to have significant improvements in pelvic pain, dysmenorrhea and dyspareunia, and a high level of satisfaction in the post-laparoscopic in women with endometriosis
  • More effective than conservative treatment in maintaining pregnancy in women with threatened miscarriage
  • Effectively improves hormone levels and related cellular immune factors in recurrent spontaneous abortion (RSA) patients
  • Regularize menstrual-cycle in women with abnormal uterine bleeding – ovulatory dysfunction

Safety Information

Adverse Reactions

  • The most common adverse events that occurs after administration of dydrogesterone are vaginal hemorrhage, nausea, vomiting, migraines or headaches, abdominal pain, menstrual complaints, and breast pain or tenderness

Contraindications

  • It is contraindicated in patients with a known hypersensitivity to dydrogesterone or any other ingredient present in formulation
  • Undiagnosed vaginal bleeding
  • Treatment for luteal support as part of an Assisted Reproductive Technology (ART) treatment should be discontinued upon diagnosis of abortion/miscarriage
  • Contraindications for the use of estrogens when used in combination with dydrogesterone

Special Precautions

  • The etiology for the bleeding should be clarified before starting the dydrogesterone treatment
  • Use dydrogesterone cautiously in patients with acute liver disease or a history of liver disease, discontinuing in severe cases
  • Breakthrough bleeding and spotting in the initial months of dydrogesterone treatment may warrant investigation, including endometrial biopsy, if they persist or recur after treatment cessation
  • Close supervision is advised for patients with a history of or predisposition to porphyria, or abnormal liver function during pregnancy or previous hormone treatment, considering potential recurrence or aggravation during dydrogesterone treatment, with discontinuation as an option
  • Patients with a history of depression may require vigilant monitoring, and if severe depression reoccurs, dydrogesterone treatment should be discontinued
  • In cases of habitual or threatened abortion, confirm fetal viability and monitor ongoing pregnancy progress and embryo vitality during treatment with dydrogesterone
  • Dydrogesterone has increased metabolism with CYP enzyme inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, efavirenz, nevirapine)
  • Perform regular physical exams (including breast and pelvic tests, mammograms, blood pressure monitoring and Pap smears) is advised before and during dydrogesterone treatment
  • Dydrogesterone may cause drowsiness or dizziness, especially after intake; use caution when driving or operating machinery

Related products